

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application:

Inventor: Kolesnikov et al.
Application No./Patent No.: 10/537,115 / 7,479,502
Filed/Issued: 03/20/2006 / 01/20/2009
Title: 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS

Confirmation No.: 8222
Examiner: Yong Liang Chu
Group Art Unit: 1626
Customer No. 021971

File No. 25922-760.831

**POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO
and 3.73 STATEMENT**

☒ I hereby appoint the practitioners associated with Customer Number:

021971

As attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO).

☒ Please address all correspondence for the above-identified application to:

021971

STATEMENT UNDER 37 CFR 3.73(b)

Pharmacyclics Inc.

a Delaware corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is: the assignee of the entire right, title and interest; in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Aleksandr Kolesnikov, Roopa Rai, William Dvorak Shrader, Steven M. Torkelson, Kieron E. Wesson, Wendy B. Young To: Axyx Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel 016923, Frame 0724, or for which a copy thereof is attached.
2. From: Axyx Pharmaceutical, Inc. To: Pharmacyclics, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel 017855, Frame 0717, or for which a copy thereof is attached.

I am an authorized representative of the:

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is incorporated herein.

SIGNATURE of Assignee of Record

Signature



Name/Title

David J. Loury/Chief Scientific Officer

Date

20 July 2010

Telephone No.